Westfield Capital Management Co. LP Buys 80,783 Shares of Haemonetics Co. (NYSE:HAE)

Westfield Capital Management Co. LP lifted its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 823,663 shares of the medical instruments supplier's stock after buying an additional 80,783 shares during the quarter. Westfield Capital Management Co. LP owned about 1.61% of Haemonetics worth $66,206,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Silvercrest Asset Management Group LLC acquired a new position in Haemonetics during the 1st quarter worth approximately $38,706,000. Price T Rowe Associates Inc. MD lifted its position in shares of Haemonetics by 38.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier's stock valued at $48,006,000 after purchasing an additional 156,665 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Haemonetics by 311.4% in the second quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier's stock valued at $2,132,000 after acquiring an additional 19,510 shares in the last quarter. Global Alpha Capital Management Ltd. purchased a new stake in shares of Haemonetics during the 3rd quarter valued at $806,000. Finally, Janus Henderson Group PLC increased its holdings in Haemonetics by 26.8% during the first quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier's stock worth $2,536,000 after buying an additional 6,287 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Up 0.1 %

Shares of Haemonetics stock traded up $0.12 during midday trading on Friday, reaching $85.55. 480,998 shares of the company's stock traded hands, compared to its average volume of 763,869. The stock has a 50 day moving average of $78.75 and a 200-day moving average of $82.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The company has a market cap of $4.30 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 1.33 and a beta of 0.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics's revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.99 earnings per share. As a group, equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They set a "buy" rating and a $112.00 price target for the company. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective on the stock in a research report on Friday, November 8th. CL King assumed coverage on Haemonetics in a research report on Friday, September 13th. They set a "buy" rating and a $116.00 price target on the stock. JMP Securities reiterated a "market outperform" rating and issued a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. Finally, Needham & Company LLC restated a "buy" rating and issued a $112.00 target price on shares of Haemonetics in a report on Friday, November 15th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Haemonetics has a consensus rating of "Moderate Buy" and a consensus price target of $107.88.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.